What a change a decade makes. Back in 2001, Gilead was a high-flying biotech, in the early legs of its growth projectory. Management at the time was laser focused on the company’s HIV franchise, deciding to sell its oncology assets to a little company called OSI Pharmaceuticals for $200 million. Since then, Gilead has grown […]
Gilead: Undervalued
Jason Chew Gilead’s stock has been in a funk. In the last three months, it has dropped 24% from about $46/share to about $35/share, this compares to a 15% drop for the Biotech HOLDERs index. It now has a PE of 11.1, lower than Pfizer, Novartis, and Sanofi Aventis, while having far higher growth and […]
